Table 2.

Distribution of TMB across cohort (excluding patients treated with immunotherapy; N = 1,415 patients).

TMB Level, N (%)a
VariableGroupPatients all TMB, N (%)LowIntermediateHighVery highPb
OverallPatients1,415960 (68%)348 (25%)58 (4%)49 (3%)
Age, y<60826 (58%)599 (73%)184 (22%)22 (3%)21 (3%)5.1 × 10−6
≥60589 (42%)361 (61%)164 (28%)36 (6%)28 (5%)
SexWomen716 (51%)485 (68%)188 (26%)29 (4%)14 (2%)0.71
Men699 (49%)475 (68%)160 (23%)29 (4%)35 (5%)
EthnicityAfrican-American53 (4%)33 (62%)18 (34%)2 (4%)0 (0%)0.55
Asian137 (10%)106 (77%)27 (20%)3 (2%)1 (1%)7.1 × 10−3
Hispanic194 (14%)147 (76%)41 (21%)5 (3%)1 (1%)5.2 × 10−3
Other60 (4%)42 (70%)16 (27%)0 (0%)2 (3%)0.59
NHW971 (69%)632 (65%)246 (25%)48 (5%)45 (5%)1.6 × 10−4
Smoking historyNo848 (60%)625 (74%)180 (21%)21 (2%)22 (3%)1.8 × 10−9
Yes567 (40%)335 (59%)168 (30%)37 (7%)27 (5%)
Type of cancerBrain150 (11%)120 (80%)26 (17%)3 (2%)1 (1%)4.4 × 10−4
Breast136 (10%)93 (68%)39 (29%)4 (3%)0 (0%)0.59
Colon/rectum141 (10%)90 (64%)44 (31%)3 (2%)4 (3%)0.44
Hematologic201 (14%)170 (85%)26 (13%)4 (2%)1 (0%)3.0 × 10−8
Lung160 (11%)82 (51%)65 (41%)9 (6%)4 (3%)1.3 × 10−5
Cutaneous90 (6%)22 (24%)23 (26%)18 (20%)27 (30%)2.2 × 10−16
Other537 (38%)383 (71%)125 (23%)17 (3%)12 (2%)0.01
GroupLow TMBIntermediate TMBHigh TMBVery high TMB
Median OS (weeks) by Cox (95% CI)From biopsyc157 (137–188)97 (79–130)151 (105–NA)384 (166–NA)
From advanced disease238 (211–306)174 (136–190)195 (125–NA)350 (209–NA)
  • Abbreviation: NA, not applicable.

  • aLow TMB defined as ≤5/Mb, intermediate TMB defined as >5 and ≤20/Mb, high TMB defined as >20 and ≤50/Mb, and very high TMB defined as >50 mutations/Mb.

  • bProbability calculated from Kruskal–Wallis as appropriate with aggregates used as reference for variables with >2 categories; significant values with Bonferroni corrected α are bolded. P values for weeks followed represent distribution of time followed between the TMB levels.

  • cPatients missing date of biopsy were omitted.